Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk

Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Nazzareno Cervelli, Giuliano Tocci, Claudio Ferri

Research output: Contribution to journalEditorial

Original languageEnglish
Pages (from-to)5-7
Number of pages3
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume25
Issue number1
DOIs
Publication statusPublished - Mar 1 2018

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{ddc5ad0208864b5fae7a7998b09da23b,
title = "Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?",
author = "Nazzareno Cervelli and Giuliano Tocci and Claudio Ferri",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s40292-017-0244-x",
language = "English",
volume = "25",
pages = "5--7",
journal = "High Blood Pressure and Cardiovascular Prevention",
issn = "1120-9879",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk

T2 - Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

AU - Cervelli, Nazzareno

AU - Tocci, Giuliano

AU - Ferri, Claudio

PY - 2018/3/1

Y1 - 2018/3/1

UR - http://www.scopus.com/inward/record.url?scp=85043371466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043371466&partnerID=8YFLogxK

U2 - 10.1007/s40292-017-0244-x

DO - 10.1007/s40292-017-0244-x

M3 - Editorial

VL - 25

SP - 5

EP - 7

JO - High Blood Pressure and Cardiovascular Prevention

JF - High Blood Pressure and Cardiovascular Prevention

SN - 1120-9879

IS - 1

ER -